Baltimore Sun
November 17, 2025
Karl Hille
Excerpt:
Maryland’s Prescription Drug Affordability Board voted Monday to restrict the price that state and local employees will have to pay for two medicines for type 2 diabetes, Jaridance and Farxiga.
The move means that after one year, the cost limit can be shared with all of Maryland under the law that established the board, said Vincent DeMarco, director of the Maryland Citizens’ Health Initiative, which advocates for affordable health care in the state.
“They did take a big step forward today,” DeMarco said. “It’s a big deal for Maryland.”
Read the full article at BaltimoreSun.com
Last modified: November 18, 2025
